SUBSCRIBE
SUBSCRIBE

Denali Therapeutics Inc.

NEWS
Biotech Bay
Why Denali Raised A $217 Million Financing Round: Not Just “Because It Could”
May 21, 2015
 · 
1 min read
Load More
AWARDS
  • NextGen Class of 2017
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
January 6, 2026
 · 
10 min read
Press Releases
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
December 30, 2025
 · 
12 min read
Press Releases
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
 · 
4 min read
Press Releases
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
 · 
3 min read
Press Releases
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 4, 2025
 · 
8 min read
Press Releases
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 6, 2025
 · 
13 min read
Press Releases
Denali Therapeutics Announces Board and Executive Leadership Updates
November 6, 2025
 · 
7 min read
Press Releases
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
October 14, 2025
 · 
6 min read
Press Releases
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 12, 2025
 · 
12 min read
Press Releases
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
July 8, 2025
 · 
8 min read
Load More